FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

AUBERTON-HERVE ANDRE-JACQUES

2. Date of Event Requiring Statement (MM/DD/YYYY)
1/24/2018 

3. Issuer Name and Ticker or Trading Symbol

Bionik Laboratories Corp. [BNKL]

(Last)        (First)        (Middle)

C/O BIONIK LABORATORIES CORP., 483 BAY STREET, N105

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                            _____ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

TORONTO, A6 M5G2C9       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

6/4/2018 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)     (1) (2) 9/1/2027   Common Stock   6107677   $0.161   I   Shares held through 4A Consulting and Engineering  

Explanation of Responses:
(1)  As of June 4, 2018, the Issuer and 4A Consulting and Engineering ("4A") entered into a First Amendment to Equity Compensation Agreement (the "Amendment"), which amended the vesting schedule of the options granted to 4A to purchase 6,107,677 shares of the Issuer's common stock, effective as of January 24, 2018. This Form 3 amendment is being filed to disclose the amended vesting schedule of the options pursuant to the Amendment. Pursuant to the Amendment, one-sixth of the option will be vested and exercisable as of the September 1, 2017 date of grant, and the unvested portion of the option will become vested and exercisable as follows: 100% in 5 equal annual installments on each of the five anniversaries of the date of the issuance of the option.
(2)  The option shall be fully vested on the occurrence of any of the following conditions: (a) A Change of Control (as defined in the Company's 2014 Equity Incentive Plan) or (b) upon Andre-Jacques Auberton-Herve, the President of 4A, not being Chairman of the Board of the Issuer for any reason.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
AUBERTON-HERVE ANDRE-JACQUES
C/O BIONIK LABORATORIES CORP.
483 BAY STREET, N105
TORONTO, A6 M5G2C9 		X



Signatures
/s/ Andre-Jacques Auberton-Herve 6/15/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Grafico Azioni Bionik Laboratories (CE) (USOTC:BNKL)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Bionik Laboratories (CE)
Grafico Azioni Bionik Laboratories (CE) (USOTC:BNKL)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Bionik Laboratories (CE)